We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?
Read MoreHide Full Article
With no marketed product, investors’ focus will likely be on commercialization plan for Avenue Therapeutics, Inc. (ATXI - Free Report) pain candidate, tramadol, when the company reports second-quarter 2020 results. In the last-reported quarter, the company delivered an earnings surprise of 52.94%.
The company’s earnings history is encouraging, with the average surprise in the last four quarters being 44.58%.
Avenue Therapeutics’ stock has risen 6.1% so far this year against the industry’s decline of 6.5%.
Factors to Note
Avenue Therapeutics is a clinical-stage biopharmaceutical company developing product principally for use in the acute/intensive care hospital setting. The company’s sole pipeline candidate, intravenous tramadol, is under review for the treatment of moderate to moderately severe post-operative pain. Since the company does not have any approved product in its candidate, the focus will be on pipeline updates when it reports second-quarter results.
The company has completed two late-stage studies evaluating tramadol in patients with moderate-to-severe pain following bunionectomy or abdominoplasty in the last two years and submitted a new drug application in December 2019. The NDA was accepted by the FDA in February and a decision is expected in October.
With successful completion of late-stage studies and a NDA submission for its sole pipeline candidate, clinical activities have declined for the company. Research & development (R&D) expenses are likely to have declined during the second quarter. However, commercialization plans following a potential approval to tramadol might have increased general and administrative expenses, offsetting a decline in R&D expenses.
We expect the company to provide update related to its commercialization plans for tramadol on its second-quarter earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Avenue Therapeutics this time around. The combination of a positive Earnings ESP, and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Avenue Therapeutics is 0.00%, as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 10 cents per share.
Zacks Rank: The company currently carries a Zacks Rank of 3.
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Translate Bio, Inc. (TBIO - Free Report) has an Earnings ESP of +5.26% and holds a Zacks Rank of 2.
Pacira BioSciences, Inc. (PCRX - Free Report) has an Earnings ESP of +28.42% and carries a Zacks Rank of 2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
What's in Store for Avenue Therapeutics (ATXI) in Q2 Earnings?
With no marketed product, investors’ focus will likely be on commercialization plan for Avenue Therapeutics, Inc. (ATXI - Free Report) pain candidate, tramadol, when the company reports second-quarter 2020 results. In the last-reported quarter, the company delivered an earnings surprise of 52.94%.
The company’s earnings history is encouraging, with the average surprise in the last four quarters being 44.58%.
Avenue Therapeutics’ stock has risen 6.1% so far this year against the industry’s decline of 6.5%.
Factors to Note
Avenue Therapeutics is a clinical-stage biopharmaceutical company developing product principally for use in the acute/intensive care hospital setting. The company’s sole pipeline candidate, intravenous tramadol, is under review for the treatment of moderate to moderately severe post-operative pain. Since the company does not have any approved product in its candidate, the focus will be on pipeline updates when it reports second-quarter results.
The company has completed two late-stage studies evaluating tramadol in patients with moderate-to-severe pain following bunionectomy or abdominoplasty in the last two years and submitted a new drug application in December 2019. The NDA was accepted by the FDA in February and a decision is expected in October.
With successful completion of late-stage studies and a NDA submission for its sole pipeline candidate, clinical activities have declined for the company. Research & development (R&D) expenses are likely to have declined during the second quarter. However, commercialization plans following a potential approval to tramadol might have increased general and administrative expenses, offsetting a decline in R&D expenses.
We expect the company to provide update related to its commercialization plans for tramadol on its second-quarter earnings call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Avenue Therapeutics this time around. The combination of a positive Earnings ESP, and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP for Avenue Therapeutics is 0.00%, as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 10 cents per share.
Zacks Rank: The company currently carries a Zacks Rank of 3.
Avenue Therapeutics, Inc. Price and Consensus
Avenue Therapeutics, Inc. price-consensus-chart | Avenue Therapeutics, Inc. Quote
Stocks to Consider
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
AcelRx Pharmaceuticals, Inc. has an Earnings ESP of +40.74% and carries a Zacks Rank #3, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Translate Bio, Inc. (TBIO - Free Report) has an Earnings ESP of +5.26% and holds a Zacks Rank of 2.
Pacira BioSciences, Inc. (PCRX - Free Report) has an Earnings ESP of +28.42% and carries a Zacks Rank of 2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>